All Outputs (62)

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial (2015)
Journal Article
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., …Bridgewater, J. A. (2015). Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The lancet oncology, 16(8), 967-978. https://doi.org/10.1016/S1470-2045%2815%2900139-4

© 2015 Valle et al. Open Access article distributed under the terms of CC BY. Background: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors... Read More about Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation (2015)
Journal Article
ElKeeb, A. M., Collier, M. E. W., Maraveyas, A., & Ettelaie, C. (2015). Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation. Thrombosis and haemostasis, 114(2), 364-378. https://doi.org/10.1160/th14-09-0795

We previously reported that high levels of tissue factor (TF) can induce cellular apoptosis in endothelial. In this study, TF-mediated mechanisms of induction of apoptosis were explored. Endothelial cells were transfected to express wild-type TF. Add... Read More about Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation.

Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease (2014)
Thesis
Hall, J. (2014). Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4216550

Cancer and its treatment are frequently complicated by the development of venous thromboembolism (VTE). Interestingly, VTE incidence rates vary according to tumour type and the chemotherapy regimen administered. Yet, the precise mechanisms responsibl... Read More about Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease.

Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control (2014)
Journal Article
Glynne-Jones, R., Counsell, N., Quirke, P., Mortensen, N., Maraveyas, A., Meadows, H. M., …Sebag-Montefiore, D. (2014). Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 25(7), 1356-1362. https://doi.org/10.1093/annonc/mdu147

Background: In stage III colon cancer, oxaliplatin/5-fluorouracil (5-FU)-based adjuvant chemotherapy (FOLFOX) improves disease-free survival (DFS) and overall survival (OS). In rectal adenocarcinoma following neoadjuvant chemoradiation (CRT), we exam... Read More about Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.

Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures (2014)
Journal Article
Ettelaie, C., Collier, M., Maraveyas, A., & Ettelaie, R. (2014). Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures. Journal of Extracellular Vesicles, 3(1), 1-14. https://doi.org/10.3402/jev.v3.23592

© 2014 Camille Ettelaie et al. Microvesicles were isolated from the conditioned media of 3 cell lines (MDA-MB-231, AsPC-1 and A375) by ultracentrifugation at a range of relative centrifugal forces, and the tissue factor (TF) protein and activity, mic... Read More about Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures.

Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles (2013)
Journal Article
Collier, M. E. W., Ettelaie, C., & Maraveyas, A. (2014). Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles. Thrombosis and haemostasis, 111(4), 647-655. https://doi.org/10.1160/TH13-09-0769

We previously reported that the incorporation of tissue factor (TF) into cell-derived microvesicles (MVs) is regulated by the phosphorylation of the cytoplasmic domain of TF. Since the cytoskeletal protein filamin-A is known to bind to the cytoplasmi... Read More about Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles.

Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity (2013)
Journal Article
Collier, M. E. W., Mah, P.-M., Xiao, Y., Maraveyas, A., & Ettelaie, C. (2013). Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Thrombosis and haemostasis, 110(5), 966-976. https://doi.org/10.1160/TH13-01-0055

In this study the uptake of tissue factor (TF)-positive microparticles by endothelial cells and the recycling of the TF component were examined. Human dermal blood endothelial cells (HDBEC) were incubated with microparticles derived from cancer cell... Read More about Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity.

p38 alpha phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles (2013)
Journal Article
Ettelaie, C., ElKeeb, A. M., Maraveyas, A., & Collier, M. E. W. (2013). p38 alpha phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles. BBA - Molecular Cell Research, 1833(3), 613-621. https://doi.org/10.1016/j.bbamcr.2012.11.010

We previously showed that the phosphorylation of Ser253 within the cytoplasmic domain of human tissue factor (TF) initiates the incorporation and release of this protein into cell-derived microparticles. Furthermore, subsequent phosphorylation of Ser... Read More about p38 alpha phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles.

Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro (2012)
Journal Article
Ettelaie, C., Collier, M. E. W., Mei, M. P., Xiao, Y. P., & Maraveyas, A. (2013). Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro. Thrombosis and haemostasis, 109(1), 61-71. https://doi.org/10.1160/TH12-05-0279

The role of tissue factor (TF)-containing microparticles in clot propagation has been established, but the ability of circulating microparticles to initiate coagulation has been disputed. However, TF-bearing microparticles, particularly endothelial-m... Read More about Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro.

The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study (2012)
Journal Article
Sheard, L., Prout, H., Dowding, D., Noble, S., Watt, I., Maraveyas, A., & Johnson, M. (2012). The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study. BMC medical ethics, 13(22), Article ARTN 22. https://doi.org/10.1186/1472-6939-13-22

Background: Cancer patients are at risk of developing blood clots in their veins - venous thromboembolism (VTE) - which often takes the form of a pulmonary embolism or deep vein thrombosis. The risk increases with advanced disease. Evidence based tre... Read More about The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study.

Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study (2012)
Journal Article
Johnson, M. J., Sheard, L., Maraveyas, A., Noble, S., Prout, H., Watt, I., & Dowding, D. (2012). Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study. BMC Medical Informatics and Decision Making, 12(75), https://doi.org/10.1186/1472-6947-12-75

Background: The treatment of cancer associated thrombosis (CAT) is well established, with level 1A evidence to support the recommendation of a low molecular weight heparin (LMWH) by daily injection for 3-6 months. However, registry data suggest compl... Read More about Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study.

Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB (2011)
Journal Article
Ettelaie, C., Fountain, D., Collier, M. E. W., ElKeeb, A. M., Xiao, Y. P., & Maraveyas, A. (2011). Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB. Biochimica et Biophysica Acta (BBA): Molecular Basis of Disease, 1812(12), 1591-1600. https://doi.org/10.1016/j.bbadis.2011.09.007

Treatment of cancer patients with low molecular weight heparin (LMWH) appears to have beneficial effects. In this study, the influence of low molecular weight heparin (LMWH) on tissue factor (TF) expression and activity in five cell lines from variou... Read More about Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB.

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer (2011)
Journal Article
Ettelaie, C., Gardiner, E., Maraveyas, A., Bozas, G., Fyfe, D., Lofts, F., Propper, D., Roy, R., Sgouros, J., Waters, J., & Wedgwood, K. (2012). Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer, 48(9), 1283-1292. https://doi.org/10.1016/j.ejca.2011.10.017

Background: Annualised figures show an up to 7-fold higher incidence of vascular thromboembolism (VTE) in patients with advanced pancreatic cancer (APC) compared to other common malignancies. Concurrent VTE has been shown to confer a worse overall pr... Read More about Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Effect of resection of localised pancreatic cancer on tissue-factor promoted pathways of thrombosis, cell invasion and angiogenesis (2011)
Thesis
Echrish, H. H. J. (2011). Effect of resection of localised pancreatic cancer on tissue-factor promoted pathways of thrombosis, cell invasion and angiogenesis. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4212008

Pancreatic (PC) is the eleventh most common malignancy in the UK but it has the poorest prognosis of all human adenocarcinoma. The autopsy, epidemiological and clinical studies have consistently identified PC as one of the most highly angiogenic and... Read More about Effect of resection of localised pancreatic cancer on tissue-factor promoted pathways of thrombosis, cell invasion and angiogenesis.

Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach. (2011)
Thesis
Murray, A. M. (2011). Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4211876

Treatment strategies for advanced malignancy remain limited in their success, despite major advances in the understanding of cancer aetiology and molecular biology. The incidence of many cancers, including melanoma, continues to rise, with a huge dem... Read More about Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach..

Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro (2011)
Journal Article
Ettelaie, C., Fountain, D., Collier, M. E. W., Beeby, E., Xiao, Y. P., & Maraveyas, A. (2011). Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro. Experimental and Therapeutic Medicine, 2(2), 363-367. https://doi.org/10.3892/etm.2011.211

Elevated expression of tissue factor (TF) has been associated with an increased risk of thrombosis in the majority of cancers. Moreover, treatment of cancer patients with low molecular weight heparin (LMWH) appears to have beneficial effects that rea... Read More about Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro.

Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy (2010)
Journal Article
Murray, A., Little, S. J., Stanley, P., Cawkwell, L., & Maraveyas, A. (2010). Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. Oncology Reports, 24(4), 1049-1058. https://doi.org/10.3892/or-00000954

Angiogenesis inhibitors may enhance the effects of low dose (metronomic) chemotherapy. However, there is a wide range of novel angiogenesis inhibitors which must be tested in combinations with oral chemotherapy agents to assess the anti-endothelial a... Read More about Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.

Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion (2010)
Journal Article
Maraveyas, A., Ettelaie, C., Echrish, H., Li, C., Gardiner, E., Greenman, J., & Madden, L. A. (2010). Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagulation and Fibrinolysis, 21(5), 452-458. https://doi.org/10.1097/mbc.0b013e328338dc49

The aim of the present study was to assess the role of tissue factor and serum-induced cell invasion in patients with advanced pancreatic cancer (APC). A cohort of 39 patients with APC, without thrombosis, receiving chemotherapy, were entered in a ra... Read More about Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (2010)
Journal Article
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., …Bridgewater, J. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine, 362(14), 1273-1281. https://doi.org/10.1056/NEJMoa0908721

BACKGROUND:There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 study involving 86 patients to compare cisplatin plus gemcitabine with gemcit... Read More about Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma (2009)
Journal Article
Weber, J., Thompson, J. A., Hamid, O., Berman, D., Amin, A., Ron, I., …O'Day, S. J. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(17), 5591-5598. https://doi.org/10.1158/1078-0432.CCR-09-1024

Purpose: Diarrhea (with or without colitis) is an immune-related adverse event (irAE) associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylacti... Read More about A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.